Novavax: to present data on its vaccines
The company has already announced that recent data on its updated XBB.1.5 COVID-19 vaccine have shown strong neutralizing antibody titers for the XBB.1.5 sub-variant, as well as for the JN.1 sub-variant currently in circulation.
Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial due to start in the second half of 2024.
Dr. Robert Walker, Novavax's Chief Medical Officer, will participate in a panel discussion on the future of COVID-19 vaccinations on April 3, exploring the benefits of developing broadly protective antigens or combination vaccines.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction